Compounds and compositions are provided that can inhibit microsomal prostaglandin E synthase-1 (mPGES-1). The compounds and compositions can reduce inflammation in a subject, such as inflammation caused by an inflammation disorder or symptoms thereof. Pharmaceutical compositions comprising the compound are also provided. Furthermore, methods are provided for reducing inflammation and/or inhibiting mPGES-1. The methods can comprise administering an effective amount of the composition to a subject.

The present invention relates to improving the processing rate of a sequencing reaction, for example in a nanopore sequencing reaction, by means of using improved nucleoside-tags. The tags are linked to the nucleoside phosphate via a Pictet Spengler reaction. Exemplary sequencing reactions that are improved by the present methods include nanopore-based nucleic acid sequencing-by-synthesis reactions.

Compounds having cytotoxic and/or anti-mitotic activity are disclosed. Methods associated with preparation and use of such compounds, as well as pharmaceutical compositions comprising such compounds, are also disclosed. Also disclosed are compositions having the structure: (T)-(L)-(D), wherein (T) is a targeting moiety, (L) is an optional linker, and (D) is a compound having cytotoxic and/or anti-mitotic activity.

Compounds having cytotoxic and/or anti-mitotic activity are disclosed. Methods associated with preparation and use of such compounds, as well as pharmaceutical compositions comprising such compounds, are also disclosed. Also disclosed are compositions having the structure: (T)-(L)-(D), wherein (T) is a targeting moiety, (L) is an optional linker, and (D) is a compound having cytotoxic and/or anti-mitotic activity.

Disclosed are compounds having a linker for increasing trans-cyclooctene stability. The linker of the invention is a three-arm linker. In some embodiments, one arm of the linker is attached to a trans-cyclooctene moiety, another arm is attached to a compound selected from the group consisting of antibodies, proteins, peptides, and peptoids, and the third arm extends into the solution.

A compound of the formula, plus devices incorporating this compound, and a method of marking such devices: ##STR00001## wherein: A represents a phenyl group, a naphthyl group, a biphenyl group or two phenyl groups linked by a C.sub.1-C.sub.8 alkyl chain; B.sup.1 and B.sup.2 in each occurrence are independently selected side chains of the structure
—(Y.sup.1).sub.n-L-(Y.sup.2).sub.m—X wherein: Y.sup.1 and Y.sup.2 in each occurrence are independently selected from O, CO.sub.2— and CH.sub.2O, m and n in each occurrence are independently selected from 0 or 1; L in each occurrence is a C.sub.2-C.sub.14 straight chain alkyl group; and X in each occurrence is an independently selected cross linkable group; C is a side chain of the structure —(Z.sup.1).sub.p-M-(Z.sup.2).sub.q-E wherein: Z.sup.1 and Z.sup.2 are independently selected from O, CO.sub.2— and CH.sub.2O, p and q in each occurrence are independently selected from 0 or 1; M is a C.sub.1-C.sub.14 straight chain alkyl group; and E comprises a charge transport group; D is a side chain of the structure —(W.sup.1).sub.r—N—(W.sup.2).sub.s—F wherein: W.sup.1 and W.sup.2 are independently selected from O, CO.sub.2— and CH.sub.2O, r and s in each occurrence are independently selected from 0 or 1; N is a C.sub.1-C.sub.14 straight chain alkyl group; and F comprises a charge transport group or light emitter group; and wherein the charge transport group E does not contain a fluorene group other than those that form part of a spirobifluorenearylamine motif.

A compound of the formula, plus devices incorporating this compound, and a method of marking such devices: ##STR00001## wherein: A represents a phenyl group, a naphthyl group, a biphenyl group or two phenyl groups linked by a C.sub.1-C.sub.8 alkyl chain; B.sup.1 and B.sup.2 in each occurrence are independently selected side chains of the structure
—(Y.sup.1).sub.n-L-(Y.sup.2).sub.m—X wherein: Y.sup.1 and Y.sup.2 in each occurrence are independently selected from O, CO.sub.2— and CH.sub.2O, m and n in each occurrence are independently selected from 0 or 1; L in each occurrence is a C.sub.2-C.sub.14 straight chain alkyl group; and X in each occurrence is an independently selected cross linkable group; C is a side chain of the structure —(Z.sup.1).sub.p-M-(Z.sup.2).sub.q-E wherein: Z.sup.1 and Z.sup.2 are independently selected from O, CO.sub.2— and CH.sub.2O, p and q in each occurrence are independently selected from 0 or 1; M is a C.sub.1-C.sub.14 straight chain alkyl group; and E comprises a charge transport group; D is a side chain of the structure —(W.sup.1).sub.r—N—(W.sup.2).sub.s—F wherein: W.sup.1 and W.sup.2 are independently selected from O, CO.sub.2— and CH.sub.2O, r and s in each occurrence are independently selected from 0 or 1; N is a C.sub.1-C.sub.14 straight chain alkyl group; and F comprises a charge transport group or light emitter group; and wherein the charge transport group E does not contain a fluorene group other than those that form part of a spirobifluorenearylamine motif.

Provided is a maleimide resin with superior solution stability. Also provided is a cured product with a superior dielectric characteristic that is obtained by curing a curable resin composition in which said maleimide resin is used. The maleimide resin expressed in formula (1). (In formula (1), each of the plurality of Rs independently represents a C1-5 alkyl group, n is the number of repetitions, and the average value thereof is 1<n<5.)

Provided is a maleimide resin with superior solution stability. Also provided is a cured product with a superior dielectric characteristic that is obtained by curing a curable resin composition in which said maleimide resin is used. The maleimide resin expressed in formula (1). (In formula (1), each of the plurality of Rs independently represents a C1-5 alkyl group, n is the number of repetitions, and the average value thereof is 1<n<5.)

This disclosure relates to inhibitors of IRES-mediated protein synthesis, compositions comprising therapeutically effective amounts of these compounds, and methods of using those compounds and compositions in treating hyperproliferative disorders, e.g., cancers. This disclosure also relates to compositions comprising inhibitors of IRES-mediated protein synthesis and mTOR inhibitors, and to methods of treating cancer by conjoint administration of inhibitors of IRES-mediated protein synthesis and mTOR inhibitors.